Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harrison

Showing results (481-490 of 583) with videos related to

Pageof 59
Sort By:
Physical Review Letters|October 15, 2008
Formation of pancakelike Ising domains and giant magnetic coercivity in ferrimagnetic LuFe2O4Weida Wu, V Kiryukhin, H-J Noh, et al.
Medicine and Science in Sports and Exercise|March 15, 2024
Mechanisms of Exercise Intolerance Across the Breast Cancer Continuum: A Pooled Analysis of Individual Patient DataJessica M Scott, Jasme Lee, Meghan G Michalski, et al.
International Journal of Cardiology. Hypertension|June 22, 2021
COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare systemJaejin An, Hui Zhou, Rong Wei, et al.
Journal of the American Heart Association|December 14, 2020
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare SystemJaejin An, Rong Wei, Hui Zhou, et al.
British Journal of Haematology|July 14, 2024
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practiceAnna L Godfrey, Nikolaos Sousos, Rebecca Frewin, et al.
European Heart Journal Open|August 3, 2022
Human immunodeficiency virus infection and risks of morbidity and death in adults with incident heart failureHarshith R Avula, Andrew P Ambrosy, Michael J Silverberg, et al.
Future Oncology (London, England)|May 5, 2022
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designJohn Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, et al.
Hemasphere|July 8, 2021
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral CenterAlesia Khan, Claire Woodley, Deepti Radia, et al.
Haematologica|January 25, 2024
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trialSrdan Verstovsek, Moshe Talpaz, Martha Wadleigh, et al.
The Lancet. Haematology|September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trialClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Pageof 59

Showing results (481-490 of 583) with videos related to

Sort By:
Pageof 59
Physical Review Letters|October 15, 2008
Formation of pancakelike Ising domains and giant magnetic coercivity in ferrimagnetic LuFe2O4Weida Wu, V Kiryukhin, H-J Noh, et al.
Medicine and Science in Sports and Exercise|March 15, 2024
Mechanisms of Exercise Intolerance Across the Breast Cancer Continuum: A Pooled Analysis of Individual Patient DataJessica M Scott, Jasme Lee, Meghan G Michalski, et al.
International Journal of Cardiology. Hypertension|June 22, 2021
COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare systemJaejin An, Hui Zhou, Rong Wei, et al.
Journal of the American Heart Association|December 14, 2020
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare SystemJaejin An, Rong Wei, Hui Zhou, et al.
British Journal of Haematology|July 14, 2024
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practiceAnna L Godfrey, Nikolaos Sousos, Rebecca Frewin, et al.
European Heart Journal Open|August 3, 2022
Human immunodeficiency virus infection and risks of morbidity and death in adults with incident heart failureHarshith R Avula, Andrew P Ambrosy, Michael J Silverberg, et al.
Future Oncology (London, England)|May 5, 2022
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designJohn Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, et al.
Hemasphere|July 8, 2021
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral CenterAlesia Khan, Claire Woodley, Deepti Radia, et al.
Haematologica|January 25, 2024
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trialSrdan Verstovsek, Moshe Talpaz, Martha Wadleigh, et al.
The Lancet. Haematology|September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trialClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Pageof 59